NAS:CLSD (USA) Also trade in: Germany

Clearside Biomedical Inc

$ 1.04 0 (0%)
Volume: 152,185 Avg Vol (1m): 456,381
Market Cap $: 39.47 Mil Enterprise Value $: 14.57 Mil
P/E (TTM): 0.00 P/B: 2.30
Earnings Power Value 0
Net Current Asset Value 0.41
Tangible Book 0.47
Projected FCF 0
Median P/S Value 1.52
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 3.48
Cash-To-Debt ranked higher than
66.79% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CLSD: 3.48
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.71, Med: 7.12, Max: 10000
Current: 3.48
0.71
10000
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CLSD: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.32, Med: 0.73, Max: 0.85
Current: 0.43
0.32
0.85
Debt-to-Equity 0.62
Debt-to-Equity ranked higher than
72.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
CLSD: 0.62
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.19, Med: 0.15, Max: 1.1
Current: 0.62
-0.19
1.1
Debt-to-EBITDA -0.12
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
CLSD: -0.12
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.35, Med: -0.14, Max: -0.04
Current: -0.12
-0.35
-0.04
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -13.42
DISTRESS
GREY
SAFE
Beneish M-Score -2.32
Not Manipulator
Manipulator

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -109064.00
Operating Margin ranked lower than
95.58% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CLSD: -109064
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -276483.33, Med: -16929.86, Max: -4845.77
Current: -109064
-276483.33
-4845.77
Net Margin % -108820.00
Net Margin ranked lower than
95.33% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CLSD: -108820
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -276060, Med: -17094.2, Max: -4977.31
Current: -108820
-276060
-4977.31
ROE % -172.62
ROE ranked lower than
82.31% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CLSD: -172.62
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -367.79, Med: -147.9, Max: -126.73
Current: -172.62
-367.79
-126.73
ROA % -118.79
ROA ranked lower than
85.42% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CLSD: -118.79
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -339.45, Med: -138.19, Max: -48.89
Current: -118.79
-339.45
-48.89
ROC (Joel Greenblatt) % -10348.94
ROC (Joel Greenblatt) ranked lower than
83.20% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CLSD: -10348.94
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -20158.4, Med: -9748.9, Max: -6483.83
Current: -10348.94
-20158.4
-6483.83
3-Year Total EBITDA Growth Rate -68.60
3-Year EBITDA Growth Rate ranked lower than
84.16% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CLSD: -24.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -48.3, Med: -42.3, Max: -24.2
Current: -24.2
-48.3
-24.2
3-Year EPS w/o NRI Growth Rate -22.00
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CLSD: -22
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -22
Current: -22
0
-22

» CLSD's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CLSD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:ALBO TSE:4563 XKRX:019175 OSTO:ONCO NAS:VCEL NAS:SBBP NAS:SNNA XPAR:ERYP ASX:CUV NAS:PIRS XPAR:VLA HKSE:08158 XBRU:CYAD LSE:ARIX ASX:VLA XKRX:168330 SHSE:600556 LSE:FARN XTER:MDG1 NAS:CRBP
Traded in other countries CLM.Germany
Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a clinical biopharmaceutical company. It is engaged in developing drug therapies to treat blinding diseases of the eye. Its product candidates focuses on diseases affecting the retina.

Ratios

Current vs industry vs history
PB Ratio 2.30
PB Ratio ranked higher than
54.37% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CLSD: 2.3
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.07, Med: 3.65, Max: 10.23
Current: 2.3
1.07
10.23
PS Ratio 525.00
PS Ratio ranked lower than
94.21% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CLSD: 525
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 189.06, Med: 759.09, Max: 8980
Current: 525
189.06
8980
EV-to-EBIT -0.21
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CLSD: -0.21
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -20.6, Med: -2.9, Max: 0.1
Current: -0.21
-20.6
0.1
EV-to-EBITDA -0.21
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CLSD: -0.21
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -20.7, Med: -2.9, Max: 0.1
Current: -0.21
-20.7
0.1
EV-to-Revenue 193.64
EV-to-Revenue ranked lower than
90.53% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CLSD: 193.64
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -144.6, Med: 513.2, Max: 7849.3
Current: 193.64
-144.6
7849.3
Current Ratio 3.04
Current Ratio ranked higher than
67.32% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CLSD: 3.04
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.38, Med: 4.57, Max: 19.69
Current: 3.04
1.38
19.69
Quick Ratio 3.04
Quick Ratio ranked higher than
67.69% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CLSD: 3.04
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.38, Med: 4.57, Max: 19.69
Current: 3.04
1.38
19.69

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -35.80
3-Year Share Buyback Rate ranked lower than
71.06% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CLSD: -35.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -35.8, Med: -27.3, Max: -26
Current: -35.8
-35.8
-26

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.23
Price-to-Tangible-Book ranked higher than
61.63% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CLSD: 2.23
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.45, Med: 4.12, Max: 8.28
Current: 2.23
1.45
8.28
Price-to-Median-PS-Value 0.69
Price-to-Median-PS-Value ranked higher than
52.65% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CLSD: 0.69
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.29, Med: 1.06, Max: 10.45
Current: 0.69
0.29
10.45
Earnings Yield (Joel Greenblatt) % -555.25
Earnings Yield (Greenblatt) ranked lower than
85.20% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CLSD: -555.25
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -7193.8, Med: -34.1, Max: 2462.9
Current: -555.25
-7193.8
2462.9

More Statistics

Revenue (TTM) (Mil) $ 0.08
EPS (TTM) $ -2.53
Beta -0.85
Volatility % 82.79
52-Week Range $ 0.95 - 11.25
Shares Outstanding (Mil) 37.6

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N